- Home
- IONS vs BPMC Comparison
IONS vs BPMC Comparison
Compare IONS & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- BPMC
- Stock Information
- Founded
- IONS 1989
- BPMC 2008
- Country
- IONS United States
- BPMC United States
- Employees
- IONS N/A
- BPMC 655
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- IONS Health Care
- BPMC Health Care
- Exchange
- IONS Nasdaq
- BPMC Nasdaq
- Market Cap
- IONS 6.0B
- BPMC 5.6B
- IPO Year
- IONS 1991
- BPMC 2015
- Fundamental
- Price
- IONS $34.34
- BPMC $88.69
- Analyst Decision
- IONS Buy
- BPMC Buy
- Analyst Count
- IONS 18
- BPMC 19
- Target Price
- IONS $62.00
- BPMC $120.79
- AVG Volume (30 Days)
- IONS 1.1M
- BPMC 735.1K
- Earning Date
- IONS 11-06-2024
- BPMC 10-30-2024
- Dividend Yield
- IONS N/A
- BPMC N/A
- EPS Growth
- IONS N/A
- BPMC N/A
- EPS
- IONS N/A
- BPMC N/A
- Revenue
- IONS $803,067,000.00
- BPMC $434,415,000.00
- Revenue This Year
- IONS N/A
- BPMC $108.13
- Revenue Next Year
- IONS $16.31
- BPMC $38.91
- P/E Ratio
- IONS N/A
- BPMC N/A
- Revenue Growth
- IONS 30.57
- BPMC 100.93
- 52 Week Low
- IONS $34.24
- BPMC $63.07
- 52 Week High
- IONS $54.44
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- IONS 26.91
- BPMC 43.37
- Support Level
- IONS $37.18
- BPMC $96.52
- Resistance Level
- IONS $40.07
- BPMC $103.55
- Average True Range (ATR)
- IONS 1.38
- BPMC 4.24
- MACD
- IONS -0.26
- BPMC 0.01
- Stochastic Oscillator
- IONS 1.58
- BPMC 35.04
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.